Ubs Asset Management Americas Inc Editas Medicine, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 897,533 shares of EDIT stock, worth $2.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

897,533

Previous 901,623 0.45%

Holding current value

$2.49 Million

Previous $4.21 Million 27.32%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $13,865 - $24,376	-4,090 Reduced 0.45%	897,533 $3.06 Million
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $3.82 Million - $5.96 Million	818,056 Added 978.92%	901,623 $4.21 Million
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $65,962 - $103,869	-9,383 Reduced 10.09%	83,567 $620,000
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $134,587 - $181,070	19,449 Added 26.46%	92,950 $725,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $47,958 - $78,657	6,822 Added 10.23%	73,501 $532,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $38,671 - $61,400	4,648 Added 7.49%	66,679 $591,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $125,819 - $200,938	10,347 Added 20.02%	62,031 $759,000
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $113,905 - $243,432	-11,402 Reduced 18.07%	51,684 $611,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $120,722 - $184,471	-4,547 Reduced 6.72%	63,086 $1.67 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $119,773 - $222,467	3,050 Added 4.72%	67,633 $2.78 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $228,260 - $413,188	7,295 Added 12.73%	64,583 $3.66 Million
Q1 2021 May 14, 2021	SELL	$39.71 - $90.58 $456,426 - $1.04 Million	-11,494 Reduced 16.71%	57,288 $2.41 Million
Q4 2020 Mar 01, 2021	BUY	$27.07 - $84.35 $318,153 - $991,365	11,753 Added 20.61%	68,782 $4.82 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $261,603 - $346,442	9,323 Added 19.54%	57,029 $1.6 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $104,895 - $194,707	5,670 Added 13.49%	47,706 $1.41 Million
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $211,891 - $466,787	14,240 Added 51.23%	42,036 $833,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $25,863 - $43,300	1,327 Added 5.01%	27,796 $823,000
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $271,431 - $323,569	12,069 Added 83.81%	26,469 $601,000
Q1 2019 May 14, 2019	SELL	$19.43 - $26.41 $3.26 Million - $4.43 Million	-167,921 Reduced 92.1%	14,400 $0
Q4 2018 Feb 13, 2019	SELL	$18.19 - $31.79 $294,168 - $514,107	-16,172 Reduced 8.15%	182,321 $4.15 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $11,806 - $16,392	-427 Reduced 0.21%	198,493 $0
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $1.19 Million - $1.56 Million	37,959 Added 23.58%	198,920 $0
Q1 2018 May 14, 2018	SELL	$29.84 - $44.08 $2.54 Million - $3.76 Million	-85,240 Reduced 34.62%	160,961 $0
Q4 2017 Feb 09, 2018	BUY	$21.89 - $31.34 $5.39 Million - $7.72 Million	246,201	246,201 $0

Others Institutions Holding EDIT

# of Institutions

245

Shares Held

56.4M

Call Options Held

399K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $190M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Editas Medicine, Inc. Transaction History